SCHEDULE: Vanguard Discloses 5.58% Stake in Cullinan Therapeutics

The Vanguard Group reported a 5.58% beneficial ownership stake in Cullinan Therapeutics Inc. common stock as of December 31, 2025.

Summary

• The Vanguard Group holds 3,298,504 shares of Cullinan Therapeutics Inc. common stock.
• This represents 5.58% of the company's outstanding common stock.
• Vanguard has shared voting power over 377,729 shares and shared dispositive power over all 3,298,504 shares.
• An internal realignment at The Vanguard Group, effective January 12, 2026, means it no longer performs portfolio management or administers proxy voting, with subsidiaries expected to report beneficial ownership separately.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a major institutional investor like Vanguard can imply a degree of market confidence and stability for Cullinan Therapeutics Inc.

Positives

• A significant institutional investment from The Vanguard Group, a major asset manager, indicates confidence in Cullinan Therapeutics Inc.
• The holding of 5.58% suggests a notable, long-term investment position.

Negatives

• The filing itself does not present any negative information regarding Cullinan Therapeutics Inc.

Risks

• No specific risks related to Cullinan Therapeutics Inc. are detailed in this beneficial ownership filing.

Future Outlook

The filing indicates that following an internal realignment on January 12, 2026, The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. going forward.

Management Comments

• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by major asset managers. Vanguard's substantial holding in Cullinan Therapeutics Inc. reflects a common strategy among large index and actively managed funds to maintain positions in publicly traded companies, particularly within the biotechnology sector, which often attracts long-term growth investors.

Comparison to Industry Standards

• Vanguard's 5.58% stake in Cullinan Therapeutics Inc. is a typical size for a passive institutional investor's holding in a mid-cap or small-cap biotechnology company, aligning with its role as a major index fund provider.
• Compared to activist investors who might take larger, more concentrated positions (e.g., over 10-15%) to influence corporate strategy, Vanguard's holding is consistent with a passive investment approach, similar to other large asset managers like BlackRock or State Street.

Stakeholder Impact

• Shareholders: Increased institutional ownership can provide stability and liquidity to the stock.
• Company Management: Awareness of a significant institutional holder may influence corporate communication and investor relations strategies.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are anticipated to report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following the internal realignment.

Key Dates

Keywords

Cullinan Therapeutics, Vanguard Group, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Investment Adviser